The National Institutes of Health (NIH) is now reconsidering its recently
implemented ethics standards, following the resignation of such high-level
NIH administrators as James F. Battey, MD, PhD, director of the NIH’s
Institute on Deafness and Other Communication Disorders, due to new conflict-of-interest
The regulations, which were to take effect this fall, would restrict
NIH employees from holding stock in pharmaceutical companies or medical entities
such as health care companies and insurers, forcing them to divest. The new
policy was designed after disclosures that some NIH scientists and administrators
had consulting arrangements with the pharmaceutical and biotechnology industries.
Hampton T. NIH Ethics Rules Revisited. JAMA. 2005;293(20):2463. doi:https://doi.org/10.1001/jama.293.20.2463-a
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: